The change of immunoactivity of dendritic cells induced by mouse 4-1BBL recombinant adenovirus

Yonsei Medical Journal

Volumn 51, Issue 4, 2010, Pages 594-598

  Youlin, Kuang ^a   Xiaodong, Weng ^a   Xiuheng, Liu ^a   Zhiyuan, Chen ^a   Hengcheng, Zhu ^a   Hui, Chen ^a   Botao, Jiang ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

4 1BBL; Adenovirus; Dendritic cell

Indexed keywords

ADENOVIRUS VECTOR; ADENOVIRUS VECTOR M4 1BBL; B7 ANTIGEN; CD86 ANTIGEN; COMPLEMENTARY DNA; INTERLEUKIN 12; INTERLEUKIN 6; PLASMID VECTOR; UNCLASSIFIED DRUG; CD137 LIGAND; CYTOKINE; MESSENGER RNA; RECOMBINANT PROTEIN;

ARTICLE; CANCER CELL CULTURE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE CONSTRUCT; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MOLECULAR CLONING; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; UPREGULATION; ADENOVIRUS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; FEMALE; GENETICS; IMMUNOLOGY; MOUSE; PHENOTYPE; PHYSIOLOGY;

4-1BB LIGAND; ADENOVIRIDAE; ANIMALS; CELL LINE; CYTOKINES; DENDRITIC CELLS; FEMALE; MICE; MICE, INBRED C57BL; PHENOTYPE; RECOMBINANT PROTEINS; RNA, MESSENGER; TRANSFECTION;

EID: 77956221935     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2010.51.4.594     Document Type: Article

References (12)

1. Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 2008;65:191-199.
2. Schwarz H. Biological activities of reverse signal transduction through CD137 ligand. J Leukoc Biol 2005;77:281-286.
3. Laderach D, Movassagh M, Johnson A, Mittler RS, Galy A. 4- 1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Int Immunol 2002;14:1155-1167.
4. Lu ZY, Condomines M, Tarte K, Nadal L, Delteil MC, Rossi JF, et al. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. Exp Hematol 2007;35:443-453.
5. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS. 4- 1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002;169:4882-4888.
6. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3:609-620.
7. Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine 2006;24:4975-4986.
8. Xiao H, Huang B, Yuan Y, Li D, Han LF, Liu Y, et al. Soluble PD- 1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 2007;13:1823-1830.
9. Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H, et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 2002;14:275-286.
10. Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol 2003;170:2912-2922.
11. Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 2008;65:191-199.
12. Hu Y, He Y, Srivenugopal KS, Fan S, Jiang Y. In vitro antitumor cytotoxic T lymphocyte response induced by dendritic cells transduced with DeltaNp73alpha recombinant adenovirus. Oncol Rep 2007;18:1085-1091.